What is Lunai Bioworks's earnings per share (EPS)?

Lunai Bioworks (LNAI) reported diluted earnings per share of $-1.08 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Lunai Bioworks Financials

LNAI

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE June

This page shows Lunai Bioworks (LNAI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI LNAI FY2025 2026-05-15

Lunai’s current mechanic is cash preservation through deep R&D cuts while financing dependence persists and liabilities exceed assets.

From FY2023 to FY2025, operating cash burn improved from -$11.8M to -$7.9M, but the operating model did not get healthier in the same proportion. R&D spend fell to $537K while SG&A still ran at $17.9M, so the narrower burn appears to come mainly from shrinking development activity rather than from a stronger self-funding business.

A large share of the asset base is goodwill: $5.96M out of $8.23M of total assets. That matters because current liabilities of $29.2M far exceed current assets of $1.05M, leaving little near-term balance-sheet flexibility.

FY2025 financing inflow of $8.38M slightly exceeded operating cash outflow of -$7.87M, which means external capital is still covering the business’s day-to-day cash needs. Yet year-end cash was only $92.7K, showing that new funding mainly plugged burn rather than rebuilding liquidity.

Financial Health Signals

Financial Profile 16/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Lunai Bioworks's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Lunai Bioworks carries a low D/E ratio of -1.39, meaning only $-1.39 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 97/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Lunai Bioworks's current ratio of 0.04 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

$-1.08

Lunai Bioworks earned $-1.08 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 18.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$93K

YoY-58.0%

5Y CAGR-59.7%

10Y CAGR-29.4%

Lunai Bioworks held $93K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

18M

Lunai Bioworks had 18M shares outstanding in fiscal year 2025. This represents a decrease of 88.8% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$537K

YoY-80.2%

5Y CAGR-35.2%

Lunai Bioworks invested $537K in research and development in fiscal year 2025. This represents a decrease of 80.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

LNAI Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$537K-80.2%	$2.7M-35.0%	$4.2M-50.3%	$8.4M-46.7%	$15.7M+234.9%	$4.7M
SG&A Expenses	$17.9M-27.2%	$24.6M+60.3%	$15.3M+6.9%	$14.3M+89.6%	$7.6M+6.1%	$7.1M
Operating Income	N/A	-$81.6M-111.7%	-$38.6M+66.8%	-$116.1M-396.0%	-$23.4M-96.3%	-$11.9M
Interest Expense	$726K-28.2%	$1.0M+74.3%	$580K+55.7%	$373K-1.8%	$380K+264.0%	$104K
Income Tax	$1K	$0	N/A	$34+100.0%	-$125K	N/A
Net Income	N/A	-$88.4M-122.8%	-$39.7M+65.0%	-$113.4M-324.5%	-$26.7M-134.1%	-$11.4M
EPS (Diluted)	$-1.08	$-0.91-28.2%	$-0.71+67.1%	$-2.16	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Revenue	$21K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	$21K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$16K-65.2%	$46K+87.9%	$24K	N/A	N/A	$161K-58.7%	$390K	N/A
SG&A Expenses	$1.4M-19.5%	$1.8M-26.7%	$2.4M	N/A	$4.2M-3.0%	$4.4M-17.9%	$5.3M	N/A
Operating Income	-$1.5M+19.0%	-$1.8M+44.9%	-$3.3M	N/A	-$4.2M+8.4%	-$4.5M+91.5%	-$53.3M	N/A
Interest Expense	$108K-11.1%	$122K-0.7%	$122K	N/A	$189K+90.8%	$99K-60.5%	$250K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$2.6M-42.9%	-$1.8M-163.8%	$2.8M	N/A	$189K+102.6%	-$7.3M+83.6%	-$44.2M	N/A
EPS (Diluted)	$-0.10-25.0%	$-0.08	$0.13	N/A	$0.00+100.0%	$-0.45+83.7%	$-2.76	N/A

LNAI Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$8.2M-95.0%	$163.1M+179.8%	$58.3M-31.1%	$84.6M-55.4%	$189.6M+6.5%	$178.1M
Current Assets	$1.0M-47.6%	$2.0M-22.1%	$2.6M-73.2%	$9.6M-54.2%	$20.9M+133.7%	$8.9M
Cash & Equivalents	$93K-58.0%	$220K-88.2%	$1.9M-79.6%	$9.2M-55.6%	$20.7M+137.6%	$8.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$6.0M-96.3%	$159.3M+1268.8%	$11.6M0.0%	$11.6M0.0%	$11.6M0.0%	$11.6M
Total Liabilities	$29.6M-5.0%	$31.2M+164.0%	$11.8M-1.8%	$12.0M-19.6%	$14.9M+26.3%	$11.8M
Current Liabilities	$29.2M-3.8%	$30.3M+175.0%	$11.0M+70.9%	$6.5M+242.1%	$1.9M+41.3%	$1.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$21.3M-116.2%	$132.0M+183.8%	$46.5M-36.0%	$72.6M-58.4%	$174.7M+5.0%	$166.3M
Retained Earnings	-$510.5M-53.5%	-$332.5M-36.2%	-$244.0M-19.4%	-$204.3M-124.8%	-$90.9M-41.6%	-$64.2M

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Total Assets	$9.9M+47.9%	$6.7M-4.2%	$7.0M-15.4%	$8.2M-93.0%	$117.7M+5.7%	$111.3M-8.6%	$121.8M-25.3%	$163.1M
Current Assets	$3.7M+625.5%	$514K-35.7%	$800K-23.5%	$1.0M-71.5%	$3.7M+114.7%	$1.7M-12.3%	$1.9M-2.5%	$2.0M
Cash & Equivalents	$3.2M+541.8%	$492K-21.3%	$625K+574.0%	$93K-90.0%	$923K+196.1%	$312K+41.3%	$221K0.0%	$220K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	$964K	N/A	N/A	N/A
Goodwill	$6.0M0.0%	$6.0M0.0%	$6.0M0.0%	$6.0M-94.7%	$112.6M+4.3%	$108.0M-8.6%	$118.2M-25.8%	$159.3M
Total Liabilities	$19.4M-4.0%	$20.2M+1.1%	$20.0M-32.4%	$29.6M+0.8%	$29.3M+0.2%	$29.3M+23.3%	$23.7M-23.8%	$31.2M
Current Liabilities	$19.3M-3.6%	$20.0M+1.4%	$19.7M-32.4%	$29.2M+1.1%	$28.8M+0.8%	$28.6M+24.2%	$23.0M-24.0%	$30.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$9.6M+29.5%	-$13.5M-3.9%	-$13.0M+38.9%	-$21.3M-124.2%	$88.4M+7.7%	$82.1M-16.3%	$98.1M-25.7%	$132.0M
Retained Earnings	-$512.0M-0.5%	-$509.4M-0.4%	-$507.6M+0.6%	-$510.5M-33.0%	-$383.7M0.0%	-$383.9M-1.9%	-$376.7M-13.3%	-$332.5M

LNAI Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$7.9M+28.2%	-$11.0M+6.8%	-$11.8M+25.2%	-$15.7M+23.7%	-$20.6M-97.1%	-$10.5M
Capital Expenditures	N/A	$70K+136.5%	$30K+477.5%	$5K-89.5%	$49K-73.5%	$184K
Free Cash Flow	N/A	-$11.0M+6.5%	-$11.8M+25.0%	-$15.7M+23.8%	-$20.7M-94.1%	-$10.6M
Investing Cash Flow	-$500K+60.3%	-$1.3M-4132.5%	-$30K-477.5%	-$5K+89.5%	-$49K+73.5%	-$184K
Financing Cash Flow	$8.4M-20.3%	$10.5M+132.9%	$4.5M+6.2%	$4.3M-87.0%	$32.6M+352.8%	$7.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Operating Cash Flow	-$1.0M+4.1%	-$1.1M+20.6%	-$1.3M+25.5%	-$1.8M-21.8%	-$1.5M+41.9%	-$2.6M-26.9%	-$2.0M+16.5%	-$2.4M
Capital Expenditures	$0	N/A	N/A	N/A	N/A	N/A	N/A	$24K
Free Cash Flow	-$1.0M	N/A	N/A	N/A	N/A	N/A	N/A	-$2.4M
Investing Cash Flow	$0+100.0%	-$1K-100.2%	$545K-43.5%	$964K	N/A	N/A	$0+100.0%	-$53K
Financing Cash Flow	$3.7M+289.8%	$950K-29.3%	$1.3M+653.2%	$178K-95.0%	$3.6M+38.3%	$2.6M+27.7%	$2.0M-17.7%	$2.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

LNAI Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-67.0%+18.3pp	-85.3%+70.9pp	-156.2%-140.9pp	-15.3%-8.4pp	-6.9%
Return on Assets	N/A	-54.2%+13.9pp	-68.1%+66.0pp	-134.0%-119.9pp	-14.1%-7.7pp	-6.4%
Current Ratio	0.04-0.0	0.07-0.2	0.23-1.3	1.48-9.6	11.08+4.4	6.70
Debt-to-Equity	-1.39-1.6	0.24-0.0	0.25+0.1	0.17+0.1	0.09+0.0	0.07
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Gross Margin	100.0%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-7054.0%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	-12278.6%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	0.2%+9.1pp	-8.8%+36.2pp	-45.1%	N/A
Return on Assets	-26.1%+0.9pp	-27.0%-67.5pp	40.5%	N/A	0.2%+6.7pp	-6.5%+29.8pp	-36.3%	N/A
Current Ratio	0.19+0.2	0.03-0.0	0.040.0	0.04-0.1	0.13+0.1	0.06-0.0	0.08+0.0	0.07
Debt-to-Equity	-2.03-0.5	-1.49+0.0	-1.53-0.1	-1.39-1.7	0.33-0.0	0.36+0.1	0.240.0	0.24
FCF Margin	-4903.3%	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$21.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.04), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Frequently Asked Questions

What is Lunai Bioworks's operating cash flow?

Lunai Bioworks (LNAI) generated -$7.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Lunai Bioworks's total assets?

Lunai Bioworks (LNAI) had $8.2M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Lunai Bioworks spend on research and development?

Lunai Bioworks (LNAI) invested $537K in research and development during fiscal year 2025.

How many shares does Lunai Bioworks have outstanding?

Lunai Bioworks (LNAI) had 18M shares outstanding as of fiscal year 2025.

What is Lunai Bioworks's current ratio?

Lunai Bioworks (LNAI) had a current ratio of 0.04 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Lunai Bioworks's debt-to-equity ratio?

Lunai Bioworks (LNAI) had a debt-to-equity ratio of -1.39 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Lunai Bioworks's cash runway?

Based on fiscal year 2025 data, Lunai Bioworks (LNAI) had $93K in cash against an annual operating cash burn of $7.9M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Lunai Bioworks's debt-to-equity ratio negative or unusual?

Lunai Bioworks (LNAI) has negative shareholder equity of -$21.3M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

How financially healthy is Lunai Bioworks?

Lunai Bioworks (LNAI) scores 16 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.